StreetInsider.com News Articles

LeonaBio presents ALS drug at development summit, plans phase 2 trial

Thu, 04 Jun 2026 07:01:08 -0400

LeonaBio Inc. (NASDAQ: LONA) announced that its Chief Medical Officer Javier San Martin presented data on the company's experimental ALS treatment at the 5th Annual ALS Drug Development Summit in Boston. The presentation covered the clinical development program for brelgometon, previously known as ATH-1105.

The company disclosed that brelgometon has received the International Nonproprietary Name designation from health authorities. The drug candidate is an oral treatment designed to modulate the neurotrophic HGF system and penetrate the brain barrier.

LeonaBio plans to initiate a Phase 2 proof-of-concept study in the second half of 2026. The randomized, double-blind, placebo-controlled trial will evaluate brelgometon's efficacy,

LeonaBio presents ALS drug at development summit, plans phase 2 trial

Thu, 04 Jun 2026 07:01:08 -0400

LeonaBio plans to initiate a Phase 2 proof-of-concept study in the second half of 2026. The randomized, double-blind, placebo-controlled trial will evaluate brelgometon's efficacy,

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

Thu, 04 Jun 2026 07:00:00 -0400

Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105

BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Javier San Martin, MD, Chief Medical Officer of LeonaBio, delivered a presentation at the 5th Annual ALS Drug Development Summit taking place June 2-4, 2026 in Boston, Massachusetts. The presentation, titled “Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies,” provided an overview of the company’s brelgometon (ATH-1105) clinical development program in

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

Thu, 04 Jun 2026 07:00:00 -0400

Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

Wed, 27 May 2026 07:00:00 -0400

BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5^th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.

Details are as follows:

5^th Annual ALS Drug Development Summit

Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies
Session Title: Redefining Biomarkers

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

Wed, 27 May 2026 07:00:00 -0400

Details are as follows:

5^th Annual ALS Drug Development Summit

Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies
Session Title: Redefining Biomarkers

Piper Sandler Starts LeonaBio (LONA) at Overweight

Wed, 27 May 2026 03:46:18 -0400

Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ: LONA) with a Overweight rating and a price target of $20.00.

The analyst comments: “LONA is advancing lasofoxifene, a selective estrogen receptor modulator (SERM) for treatment of ER+/HER2- mBC (~120k U.S. patients/year). LONA is a late-clinical stage biotech company well-positioned to compete in the large ER+/HER2- mBC market. Lead asset, lasofoxifene, is a 3rd generation SERM that is distinct from prior SERMs due to its: (i) tissue selectivity that allows for potent antagonism in breast tissue while sparing ER signaling in bone and vaginal tissue, (ii) unique receptor-stabilizing mechanism that has

Piper Sandler Starts LeonaBio (LONA) at Overweight

Wed, 27 May 2026 03:46:18 -0400

Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ: LONA) with a Overweight rating and a price target of $20.00.

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:05:00 -0400

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027

On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026

Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene

BOTHELL, Wash., May 07,

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:05:00 -0400

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026

Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene

BOTHELL, Wash., May 07,

LeonaBio adds three directors to board, John Fluke retires

Thu, 07 May 2026 09:20:58 -0400

LeonaBio Inc. (NASDAQ: LONA) appointed Fred Callori, Natalie Holles and Peter Silverman to its board of directors effective May 5, according to a company statement. The appointments coincide with the retirement of John Fluke Jr., who served on the board since 2014 and stepped down May 4.

Callori serves as partner and managing director at Perceptive Advisors LLC, an investment firm specializing in biotechnology stocks, since January 2018. He previously held senior roles at Xontogeny LLC and was a partner at Choate, Hall & Stewart LLP from 1998 to 2017. Callori holds a law degree from Boston University School of Law.

Holles

LeonaBio adds three directors to board, John Fluke retires

Thu, 07 May 2026 09:20:58 -0400

Holles

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

Thu, 07 May 2026 09:20:00 -0400

BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026.